Anupam Rasayan Acquires 48.2% Stake in Bliss GVS Pharma

Revenue to exceed ₹4,000 crore with a pro-forma EBITDA of approximately ₹834 crore.

Reader Takeaway: Forward integration provides new revenue streams, though integration of four distinct business units poses operational challenges.

What just happened

Anupam Rasayan India Ltd has successfully closed its acquisition of a 48.2% controlling stake in Bliss GVS Pharma. The transaction was valued at ₹299 per share and finalized on September 28, 2026. This acquisition is the third major inorganic move for Anupam Rasayan, following previous investments in Tanfac Industries and Jayhawk Fine Chemicals, effectively shifting the company's focus toward finished pharmaceutical formulations.

Why this matters

The deal creates a diversified platform capable of generating over ₹4,000 crore in revenue. By integrating Bliss GVS’s portfolio of over 150 brands and its six US FDA and WHO-GMP certified facilities, Anupam Rasayan secures an end-to-end value chain. This allows the company to move beyond specialty chemicals and intermediates directly into consumer-facing pharmaceutical dosages.

Acquisition Financing

To maintain balance sheet health, the company utilized a mix of debt and specialized equity. This includes a ₹300 crore term loan and approximately ₹1,450 crore raised through non-controlling, non-voting instruments from investors like Bain Capital, Trust Group, and Investec.

Risks to watch

Success hinges on managing operational synergies across four distinct entities. Furthermore, while Bliss GVS’s 30% capacity utilization offers significant room for volume growth, it also highlights the need for the management team to efficiently optimize under-performing manufacturing assets in Maharashtra.

Context Metrics

Following the acquisition, the platform’s revenue composition includes ₹1,676 crore from Anupam Rasayan (standalone), ₹927 crore from Bliss GVS Pharma, ₹722 crore from Jayhawk Fine Chemicals, and ₹711 crore from Tanfac Industries.